Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-988594.00 · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-116.2%
↓Gross Margin
-253.8%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+876.9%
FCF CAGR
—
FCF margin
-702.3%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $140760.0 · net income $-1.9M · FCF $-988594.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $140760.00 | $140760.00 | $61482.00 | $269239.00 | $151.00 |
| Net Income | $-1.9M | $-1.9M | $-1.2M | $-1.4M | $-2.9M |
| EBITDA | $-1.8M | $-1.8M | $-1.2M | $-1.4M | $-2.8M |
| EPS | -0.02 | -0.02 | -0.02 | -0.03 | -0.10 |
| Gross Margin | -253.8% | -253.8% | -409.8% | -57.0% | 66.2% |
| Operating Margin | -1284.2% | -1284.2% | -1919.6% | -404.7% | -539706.6% |
| Net Margin | -1340.7% | -1340.7% | -1990.9% | -525.1% | -1892598.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 37.83 | 0.11 | 0.05 |
| Current Ratio | 1206.70 | 1206.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-988594.00 | $-988594.00 | $-620362.00 | $-1.4M | $-884865.00 |
| Returns | |||||
| ROE | -116.2% | -116.2% | -20192.3% | -150.0% | -161.3% |
| Valuation | |||||
| P/B | 1.59 | 1.59 | 136.18 | 5.60 | 2.33 |
| Growth & Yield | |||||
| Revenue Growth | 128.9% | 128.9% | -77.2% | 178204.0% | — |
| EPS Growth | 0.0% | 0.0% | 33.3% | 70.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
-25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.